Navigation Links
Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
Date:3/4/2008

Broad-based alliance to develop products for a wide range of animal species

PLEASANTON, Calif., March 4 /PRNewswire/ -- The Animal Health Division of Bayer HealthCare AG and Juvaris BioTherapeutics, Inc. jointly announced today that the companies have executed a broad-based licensing agreement. Under the terms of the agreement, Bayer HealthCare will have complete access in the veterinary field to the Juvaris mono-immunotherapy and vaccine technology, which is being developed by Juvaris for human health care. The companies will evaluate and execute product development programs directed at immune stimulation and disease prevention in a variety of animal species.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080304/LATU063LOGO-a)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080304/LATU063LOGO-b)

In addition, the agreement anticipates that Bayer Animal Health will help financially support Juvaris' research, product formulation, development and GMP manufacturing activities to support its alliance obligations. The license is worldwide in scope. The financial terms of the deal have not been disclosed.

In commenting on the transaction, Lykele van der Broek, President of Bayer's Animal Health Division and Member of the Executive Committee of Bayer HealthCare AG said, "We are excited about the opportunities the Juvaris technology offers us. The beauty about this cooperation is, that it is not just about one single product. It serves as a platform technology that helps us develop a wide range of applications in several species for numerous indications in preventing infectious diseases. This technology in combination with our in-house expertise dramatically expands our ability to develop new and innovative products that promote immune stimulation and disease prevention."
'/>"/>

SOURCE Juvaris BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
2. Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation
3. Bayer Corporation Renames Its U.S. Foundation, Refocuses Charitable Giving Areas
4. New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools
5. New Bayer, United Nations Partnership Brings International Environment and Art Competition to Pittsburgh-Area Elementary and Middle Schools
6. New Bayer, United Nations Partnership Brings International Environment and Art Competition to Northern New Jersey Elementary and Middle Schools
7. New Bayer, United Nations Partnership Brings International Environment and Art Competition to Kansas City Area Elementary and Middle Schools
8. AUDIO from Medialink and Bayer: Use Caution When Choosing Your Cold Medicine
9. Bayer CropScience, Mertec and M.S. Technologies to Co-Develop New Soybean Trait Products
10. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
11. Bayer Awards Making Science Make Sense Grant to Girl Scouts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...r Seeks to Raise $38 Million for Life-threatening,...wire/ -- Walkers in nearly,every state will raise ...nd,18 -- by participating in GREAT STRIDES, the la... Foundation announced today., May is National Cys...,life-threatening genetic disease that causes fata...
(Date:5/16/2008)...s is more unemployed politicians - and economists,... Although nearly all,voters place health care at t...oming federal budgetary crunch means none of the h...esidential candidates is likely to become,law anyt...Bill Frist., Jousting with Princeton University H...
(Date:5/16/2008)...PRNewswire-USNewswire/ -- As tropical storms,conti...elta, survivors of,Cyclone Nargis are vulnerable t...rs still need assistance, as exposure to the foul ...gly dire situation., "The people living in these ... this disaster and get back on their feet," said D...
(Date:5/16/2008)...., May 16 /PRNewswire-FirstCall/ -- Nationwide,Hea... the promotion of David,M. Boitano to Senior Vice ... made a tremendous contribution to NHP over the la...ment growth and diversification strategy,successes... accretive,investments for NHP, leveraging his vas...
Breaking Medicine News(10 mins):Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:David M. Boitano Promoted to Senior Vice President 2
...has issued a temporary regulation on human organ t... organ trade, under control // and regulate transp...s regarding organ transplantation and donation wou...y in the best interest of the patients. The new r...
... that lifted up faces and brought cheer to the Chu... tabs for three types of obesity surgery, in case...ms. // But the catch is that, only surgeries perf...ons or the American Society of Bariatric Surgery w...
...irst to chair some healthy practices in classrooms...stand for hours a day. // This follows a study, wh... to significant weight loss, as against sitting wh.... According to researchers, children were capable ...
... in the May 1, 2006 issue of CANCER, a peer-review...t weight training// improves the quality of life o... cancer. A bi-weekly exercise regimen for six mont...tional condition of the patients. In the initial ...
Other Medicine News:Health News:China Issues New Legislation To Ban Human Organ Trade 2Health News:Welcome to ‘Stand Only’ Classrooms That Exercise The Brain And The Bod 2
(Date:5/15/2008)...d with a newly cleared device to identify the, li... are associated with complicatio...5 /- InfraReDx, Inc. today,announced ... Mich., have,successfully used its LipiScan(TM) Co...rdiac catheterization. This is the first patient i...
(Date:5/15/2008)...May 15 /- Ergonex Pharma today,announ...ation (FDA) has,granted orphan drug designation to... hypertension (PAH). Terguride is currently being ...urope., "The FDA,s grant of orphan drug designati... our development program by offering regulatory,c...
(Date:5/15/2008)...y 15 /- Tigris Pharmaceuticals,Inc. ...earch and,Development Agreement (CRADA) with the N...linical and preclinical development of AFP-464, an...P-464 is converted to,metabolites which bind coval...tosis., This is part of a four-year CRADA encompa...
(Date:5/15/2008)...ains for an Antiplatelet Therapy that, Combined, w...tion of Plavix/Iscover and Aspirin, According ... Mass., May 15 /- Decision Resources,...firms for pharmaceutical and,healthcare issues, fi...,improvement in patient compared to Sanofi-Aventis...
Breaking Medicine Technology:First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Up for Debate This Week 3A National Service Mental Health Coverage and Consumer Product Safety 13227 1Up for Debate This Week 3A National Service Mental Health Coverage and Consumer Product Safety 13227 2Up for Debate This Week 3A National Service Mental Health Coverage and Consumer Product Safety 13227 3Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 3645 1Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 3645 2Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 3645 3Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 3645 4Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 3645 5Gentiva 28R 29 Health Services Completes Acquisition of Major Home Health Provider in CON State of Mississippi 13224 1Gentiva 28R 29 Health Services Completes Acquisition of Major Home Health Provider in CON State of Mississippi 13224 2Gentiva 28R 29 Health Services Completes Acquisition of Major Home Health Provider in CON State of Mississippi 13224 3Prime Healthcare Services Enters Into Network Wide Contract With Aetna Health Plans 13222 1Prime Healthcare Services Enters Into Network Wide Contract With Aetna Health Plans 13222 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 11 mm.
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 8.7 mm.
Medicine Products: